NasdaqCM - Delayed Quote USD

Bright Minds Biosciences Inc. (DRUG)

32.49
+0.43
+(1.34%)
At close: May 9 at 4:00:01 PM EDT
33.20
+0.71
+(2.19%)
After hours: May 9 at 7:37:50 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for DRUG

Recent News: DRUG

View More
Psychedelic: Compass, GH Research, MindMed report quarterly earnings

Psychedelic: Compass, GH Research, MindMed report quarterly earnings
TipRanks yesterday
Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
GlobeNewswire 12 days ago
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research
GlobeNewswire 2 months ago
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March
GlobeNewswire 2 months ago
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
GlobeNewswire 3 months ago
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
GlobeNewswire 5 months ago
Bright Minds Biosciences Secures $35 Million Investment

Bright Minds Biosciences Secures $35 Million Investment
TipRanks 5 months ago
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
GlobeNewswire 6 months ago
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
GlobeNewswire 6 months ago
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
GlobeNewswire 6 months ago
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
GlobeNewswire 6 months ago
View More

Related Tickers

MNPR Monopar Therapeutics Inc.
39.42
-6.96%
 
TVGN Tevogen Bio Holdings Inc.
1.0900
0.00%
 
DWTX Dogwood Therapeutics, Inc.
4.5600
0.00%
 
BIVI BioVie Inc.
1.1200
-8.94%
 
CADL Candel Therapeutics, Inc.
4.8100
+1.05%
 
GLMD Galmed Pharmaceuticals Ltd.
1.2400
-0.80%
 
TOVX Theriva Biologics, Inc.
0.5299
-17.61%
 
PLRZ Polyrizon Ltd.
0.3747
-36.58%
 
TPST Tempest Therapeutics, Inc.
6.49
-5.26%
 
TNXP Tonix Pharmaceuticals Holding Corp.
18.83
-0.58%